The management of classical Hodgkin's lymphoma: Past, present, and future

Advances in Hematology

Volumn 2011, Issue , 2011, Pages

  McNamara, C ^a   Richardson, S E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BLEOMYCIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CHLORMETHINE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRATUMUMAB; LENALIDOMIDE; MELPHALAN; MOCETINOSTAT; PANOBINOSTAT; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; SGN 30; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VORINOSTAT;

ADD ON THERAPY; ADVANCED CANCER; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMOSENSITIVITY; CLASSICAL HODGKIN LYMPHOMA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG FATALITY; FERTILITY; GRAFT VERSUS HOST REACTION; HUMAN; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

EID: 79959305089     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2011/865870     Document Type: Review

References (102)

1. Hasenclever D., Diehl V., A prognostic score for advanced Hodgkin's disease New England Journal of Medicine 1998 339 21 1506 1514 (Pubitemid 28543499)
2. Henry-Amar M., Aeppli D. M., Anderson J., Somers R., Henry-Amar M., Meerwaldt J. K., Carde P., Long term survival and study of causes of death Treatment Strategy in Hodgkins Disease 1990 London, UK John Libbey and Co 381 418
3. Press O. W., LeBlanc M., Lichter A. S., Grogan T. M., Unger J. M., Wasserman T. H., Gaynor E. R., Peterson B. A., Miller T. P., Fisher R. I., Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease Journal of Clinical Oncology 2001 19 22 4238 4244 (Pubitemid 33081641)
4. Engert A., Franklin J., Eich H. T., Brillant C., Sehlen S., Cartoni C., Herrmann R., Pfreundschuh M., Sieber M., Tesch H., Franke A., Koch P., De Wit M., Paulus U., Hasenclever D., Loeffler M., Mller R. -P., Mller-Hermelink H. K., Dhmke E., Diehl V., Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial Journal of Clinical Oncology 2007 25 23 3495 3502 (Pubitemid 47310889)
5. Noordijk E. M., Carde P., Dupouy N., Hagenbeek A., Krol A. D. G., Kluin-Nelemans J. C., Tirelli U., Monconduit M., Thomas J., Eghbali H., Aleman B. M. P., Bosq J., Vovk M., Verschueren T. A. M., Pny A. M., Girinsky T., Raemaekers J. M. M., Henry-Amar M., Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials Journal of Clinical Oncology 2006 24 19 3128 3135 (Pubitemid 46638951)
6. Ferm C., Eghbali H., Meerwaldt J. H., Rieux C., Bosq J., Berger F., Girinsky T., Brice P., Van'T Veer M. B., Walewski J. A., Lederlin P., Tirelli U., Carde P., Van Den Neste E., Gyan E., Monconduit M., Divin M., Raemaekers J. M. M., Salles G., Noordijk E. M., Creemers G. J., Gabarre J., Hagenbeek A., Reman O., Blanc M., Thomas J., Vi B., Kluin-Nelemans J. C., Viseu F., Baars J. W., Poortmans P., Lugtenburg P. J., Carrie C., Jaubert J., Henry-Amar M., Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease New England Journal of Medicine 2007 357 19 1916 1927 (Pubitemid 350074687)
7. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., Valagussa P., ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results Journal of Clinical Oncology 2004 22 14 2835 2841 (Pubitemid 41079901)
8. Meyer R. M., Gospodarowicz M. K., Connors J. M., Pearcey R. G., Bezjak A., Wells W. A., Burns B. F., Winter J. N., Horning S. J., Dar A. R., Djurfeldt M. S., Ding K., Shepherd L. E., Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2005 23 21 4634 4642 (Pubitemid 46237440)
9. Straus D. J., Portlock C. S., Qin J., Myers J., Zelenetz A. D., Moskowitz C., Noy A., Goy A., Yahalom J., Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 2004 104 12 3483 3489 (Pubitemid 39564416)
10. Herbst C., Rehan F. A., Brillant C., Bohlius J., Skoetz N., Schulz H., Monsef I., Specht L., Engert A., Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review Haematologica 2010 95 3 494 500
11. Engert A., Pltschow A., Eich H. T., Lohri A., Drken B., Borchmann P., Berger B., Greil R., Willborn K. C., Wilhelm M., Debus J., Eble M. J., Skler M., Ho A., Rank A., Ganser A., Trmper L., Bokemeyer C., Kirchner H., Schubert J., Krl Z., Fuchs M., Mller-Hermelink H. -K., Mller R. -P., Diehl V., Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma New England Journal of Medicine 2010 363 7 640 652
12. Carde P., Hagenbeek A., Hayat M., Monconduit M., Thomas J., Burgers M. J. V., Noordijk E. M., Tanguy A., Meerwaldt J. H., Le Fur R., Somers R., Kluin- Nelemans H. C., Busson A., Breed W. P., Bron D., Holdrinet A., Rutten E. H. J. M., Michiels J. J., Regnier R., Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group Journal of Clinical Oncology 1993 11 11 2258 2272 (Pubitemid 23332265)
13. Engert A., Schiller P., Josting A., Herrmann R., Koch P., Sieber M., Boissevain F., De Wit M., Mezger J., Dhmke E., Willich N., Mller R. -P., Schmidt B. F., Renner H., Mller-Hermelink H. K., Pfistner B., Wolf J., Hasenclever D., Lffler M., Diehl V., Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group Journal of Clinical Oncology 2003 21 19 3601 3608 (Pubitemid 46594052)
14. Longo D. L., Young R. C., Wesley M., Twenty years of MOPP therapy for Hodgkin's disease Journal of Clinical Oncology 1986 4 9 1295 1306 (Pubitemid 16028022)
15. Bonadonna G., Valagussa P., Santoro A., Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results Annals of Internal Medicine 1986 104 6 739 746 (Pubitemid 16115035)
16. Canellos G. P., Anderson J. R., Propert K. J., Nissen N., Cooper M. R., Henderson E. S., Green M. R., Gottlieb A., Peterson B. A., Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD New England Journal of Medicine 1992 327 21 1478 1484
17. Viviani S., Bonadonna G., Santoro A., Bonfante V., Zanini M., Devizzi L., Soncini F., Valagussa P., Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results Journal of Clinical Oncology 1996 14 5 1421 1430 (Pubitemid 26134197)
18. Connors J. M., Klimo P., Adams G., Burns B. F., Cooper I., Meyer R. M., O'Reilly S. E., Pater J., Quirt I., Sadura A., Shustik C., Skillings J., Sutcliffe S., Verma S., Yoshida S., Zee B., Treatment of advanced Hodgkin's disease with chemotherapycomparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology 1997 15 4 1638 1645 (Pubitemid 27167404)
19. Duggan D. B., Petroni G. R., Johnson J. L., Glick J. H., Fisher R. I., Connors J. M., Canellos G. P., Peterson B. A., Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial Journal of Clinical Oncology 2003 21 4 607 614 (Pubitemid 46621893)
20. Diehl V., Sieber M., Rffer U., Lathan B., Hasenclever D., Pfreundschuh M., Loeffler M., Lieberz D., Koch P., Adler M., Tesch H., BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease Annals of Oncology 1997 8 2 143 148 (Pubitemid 27112881)
21. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., Tesch H., Herrmann R., Drken B., Mller-Hermelink H. -K., Dhmke E., Loeffler M., Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease New England Journal of Medicine 2003 348 24 2386 2395 (Pubitemid 36682817)
22. Engert A., Diehl V., Franklin J., Lohri A., Drken B., Ludwig W. D., Koch P., Hnel M., Pfreundschuh M., Wilhelm M., Trmper L., Aulitzky W. E., Bentz M., Rummel M., Sezer O., Mller-Hermelink H. K., Hasenclever D., Lffler M., Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 study Journal of Clinical Oncology 2009 27 27 4548 4554
23. Ballova V., Rffer J. U., Haverkamp H., Pfistner B., Mller-Hermelink H. K., Dhmke E., Worst P., Wilhelmy M., Naumann R., Hentrich M., Eich H. T., Josting A., Lffler M., Diehl V., Engert A., A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9) Annals of Oncology 2005 16 1 124 131 (Pubitemid 40124489)
24. Federico M., Luminari S., Iannitto E., Polimeno G., Marcheselli L., Montanini A., Sala A. L., Merli F., Stelitano C., Pozzi S., Scalone R., Renzo N. D., Musto P., Baldini L., Cervetti G., Angrilli F., Mazza P., Brugiatelli M., Gobbi P. G., ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced hodgkin's lymphoma: results from the HD2000 gruppo italiano Per lo studio dei linfomi trial Journal of Clinical Oncology 2009 27 5 805 811
25. Diehl V., Haverkamp H., Mueller R. P., Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients with advanced stage Hodgkins lymphoma (HL): final analysis of the randomised HD12 trial of the German Hodgkin Study Group (GHSG) Blood 2008 112, abstract 1558
26. Gianni A. M., Rambaldi A., Zinzami P., Comparable 3 year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomised trial of the Michelangelo, GITIL and IIL cooperative groups Journal of Clinical Oncology 2008 26, abstract 8506
27. Sieber M., Bredenfeld H., Josting A., Reineke T., Rueffer U., Koch T., Naumann R., Boissevain F., Koch P., Worst P., Soekler M., Eich H., Mller-Hermelink H. K., Franklin J., Paulus U., Wolf J., Engert A., Diehl V., 14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group Journal of Clinical Oncology 2003 21 9 1734 1739 (Pubitemid 46638585)
28. Horning S. J., Hoppe R. T., Breslin S., Bartlett N. L., William Brown B., Rosenberg S. A., Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial Journal of Clinical Oncology 2002 20 3 630 637 (Pubitemid 34111368)
29. Horning S. J., Williams J., Bartlett N. L., Bennett J. M., Hoppe R. T., Neuberg D., Cassileth P., Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492 Journal of Clinical Oncology 2000 18 5 972 980 (Pubitemid 30123772)
30. Gobbi P. G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., Pavone V., Cavanna L., Santini G., Merli F., Liberati M., Baldini L., Deliliers G. L., Angelucci E., Bordonaro R., Federico M., ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi Journal of Clinical Oncology 2005 23 36 9198 9207
31. Hoskin P. J., Lowry L., Horwich A., Jack A., Mead B., Hancock B. W., Smith P., Qian W., Patrick P., Popova B., Pettitt A., Cunningham D., Pettengell R., Sweetenham J., Linch D., Johnson P. W. M., Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 Journal of Clinical Oncology 2009 27 32 5390 5396
32. Johnson P. W. M., Radford J. A., Cullen M. H., Sydes M. R., Walewski J., Jack A. S., MacLennan K. A., Stenning S. P., Clawson S., Smith P., Ryder D., Hancock B. W., Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519) Journal of Clinical Oncology 2005 23 36 9208 9218
33. Aleman B. M. P., Raemaekers J. M. M., Tomisic R., Baaijens M. H. A., Bortolus R., Lybeert M. L. M., van der Maazen R. W. M., Girinsky T., Demeestere G., Lugtenburg P., Lievens Y., de Jong D., Pinna A., Henry-Amar M., Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma International Journal of Radiation Oncology Biology Physics 2007 67 1 19 30 (Pubitemid 44959502)
34. Ferm C., Mounier N., Casasnovas O., Brice P., Divine M., Sonet A., Bouafia F., Bastard-Stamatoullas A., Bordessoule D., Voillat L., Reman O., Blanc M., Gisselbrecht C., Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood 2006 107 12 4636 4642 (Pubitemid 43882608)
35. Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., Klutmann S., Knapp W. H., Zijlstra J. M., Bockisch A., Weckesser M., Lorenz R., Schreckenberger M., Bares R., Eich H. T., Mueller R. P., Fuchs M., Borchmann P., Schicha H., Diehl V., Engert A., Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood 2008 112 10 3989 3994
36. Loeffler M., Brosteanu O., Hasenclever D., Sextro M., Assouline D., Bartolucci A. A., Cassileth P. A., Crowther D., Diehl V., Fisher R. I., Hoppe R. T., Jacobs P., Pater J. L., Pavlovsky S., Thompson E., Wiernik P., Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease Journal of Clinical Oncology 1998 16 3 818 829 (Pubitemid 28108713)
37. Terasawa T., Lau J., Bardet S., Couturier O., Hotta T., Hutchings M., Nihashi T., Nagai H., Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review Journal of Clinical Oncology 2009 27 11 1906 1914
38. Proctor S. J., Mackie M., Dawson A., White J., Prescott R. J., Lucraft H. L., Angus B., Jackson G. H., Lennard A. L., Hepplestone A., Taylor P. R. A., A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III) European Journal of Cancer 2002 38 6 795 806 (Pubitemid 34280325)
39. Federico M., Bellei M., Brice P., Brugiatelli M., Nagler A., Gisselbrecht C., Moretti L., Colombat P., Luminari S., Fabbiano F., Di Renzo N., Goldstone A., Carella A. M., High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy Journal of Clinical Oncology 2003 21 12 2320 2325 (Pubitemid 46621870)
40. Hodgson D. C., Pintilie M., Gitterman L., DeWitt B., Buckley C. A., Ahmed S., Smith K., Schwartz A., Tsang R. W., Crump M., Wells W., Sun A., Gospodarowicz M. K., Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy Hematological Oncology 2007 25 1 11 15 (Pubitemid 46474309)
41. Van Der Kaaij M. A. E., Heutte N., Le Stang N., Raemaekers J. M. M., Simons A. H. M., Carde P., Noordijk E. M., Ferm C., Thomas J., Eghbali H., Kluin-Nelemans H. C., Henry-Amar M., Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'tude des Lymphomes de l'Adulte Journal of Clinical Oncology 2007 25 19 2825 2832 (Pubitemid 47134677)
42. Sieniawski M., Reineke T., Nogova L., Josting A., Pfistner B., Diehl V., Engert A., Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG) Blood 2008 111 1 71 76
43. Behringer K., Wildt L., Mueller H., Mattle V., Ganitis P., van den Hoonaard B., Ott H. W., Hofer S., Pluetschow A., Diehl V., Engert A., Borchmann P., No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group Annals of Oncology 2010 21 10 2052 2060
44. Canellos G. P., Duggan D., Johnson J., Niedzwiecki D., How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? Journal of Clinical Oncology 2004 22 8 1532 1533 (Pubitemid 41103643)
45. Gallamini A., Hutchings M., Rigacci L., Specht L., Merli F., Hansen M., Patti C., Loft A., Di Raimondo F., D'Amore F., Biggi A., Vitolo U., Stelitano C., Sancetta R., Trentin L., Luminari S., Iannitto E., Viviani S., Pierri I., Levis A., Early interim 2-[ 18 F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study Journal of Clinical Oncology 2007 25 24 3746 3752 (Pubitemid 47372616)
46. Dann E. J., Bar-Shalom R., Tamir A., Haim N., Ben-Shachar M., Avivi I., Zuckerman T., Kirschbaum M., Goor O., Libster D., Rowe J. M., Epelbaum R., Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome Blood 2007 109 3 905 909 (Pubitemid 46220633)
47. Ansell S. M., Armitage J. O., Management of Hodgkin lymphoma Mayo Clinic Proceedings 2006 81 3 419 426 (Pubitemid 43334638)
48. Longo D. L., Duffey P. L., Young R. C., Hubbard S. M., Ihde D. C., Glatstein E., Phares J. C., Jaffe E. S., Urba W. J., DeVita V. T., Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure Journal of Clinical Oncology 1992 10 2 210 218
49. Bonfante V., Santoro A., Viviani S., Devizzi L., Balzarotti M., Soncini F., Zanini M., Valagussa P., Bonadonna G., Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD Journal of Clinical Oncology 1997 15 2 528 534 (Pubitemid 27074219)
50. Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMillan A., Chopra R., Milligan D., Vaughan Hudson G., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 1993 341 8852 1051 1054 (Pubitemid 23114397)
51. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A. M., Haenel M., Boissevain F., Zschaber R., Mller P., Kirchner H., Lohri A., Decker S., Koch B., Hasenclever D., Goldstone A. H., Diehl V., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Lancet 2002 359 9323 2065 2071 (Pubitemid 34680969)
52. Gopal A. K., Metcalfe T. L., Gooley T. A., Pagel J. M., Petersdorf S. H., Bensinger W. I., Holmberg L., Maloney D. G., Press O. W., High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma the seattle experience Cancer 2008 113 6 1344 1350
53. Brice P., Divine M., Simon D., Coiffier B., Leblond V., Simon M., Voilat L., Devidas A., Morschhauser F., Rohrlich P., Andr M., Lepage E., Ferme C., Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD) Annals of Oncology 1999 10 12 1485 1488 (Pubitemid 30017059)
54. Morschhauser F., Brice P., Ferm C., Divin M., Salles G., Bouabdallah R., Sebban C., Voillat L., Casasnovas O., Stamatoullas A., Bouabdallah K., Andr M., Jais J. P., Cazals-Hatem D., Gisselbrecht C., Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group Journal of Clinical Oncology 2008 26 36 5980 5987
55. Josting A., Rudolph C., Mapara M., Glossmann J. P., Sienawski M., Sieber M., Kirchner H. H., Drken B., Hossfeld D. K., Kisro J., Metzner B., Berdel W. E., Diehl V., Engert A., Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) Annals of Oncology 2005 16 1 116 123 (Pubitemid 40124488)
56. Josting A., Rudolph C., Reiser M., Mapara M., Sieber M., Kirchner H. H., Drken B., Hossfeld D. K., Diehl V., Engert A., Wagner A., Brendel A., Illiger A., Fischer A., Heit A., Bck A., Grote-Metke A., Abedinpour A., Reiss A., Heidemann A., Benhr A., Dhrsen A., Trmper A., Schmiegel A., Ko A., Nahler A., Knuth A., Doberauer A., Fauser A., Uppenkamp A., Franke A., von Schilling A., Pralle A., Schmol A., Ganser A., Ho A., Pfreundschuh A., Hiddemann A., Frickhofen A., Horst-Schmidt A., Time-intensified dexamethasone/cisplatin/ cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease Annals of Oncology 2002 13 10 1628 1635 (Pubitemid 35331462)
57. Moskowitz C. H., Nimer S. D., Zelenetz A. D., Trippett T., Hedrick E. E., Filippa D. A., Louie D., Gonzales M., Walits J., Coady-Lyons N., Qin J., Frank R., Bertino J. R., Goy A., Noy A., O'Brien J. P., Straus D., Portlock C. S., Yahalom J., A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Blood 2001 97 3 616 623 (Pubitemid 32113392)
58. Proctor S. J., Jackson G. H., Lennard A., Angus B., Wood K., Lucraft H. L., White J., Windebank K., Taylor P. R. A., Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK) Annals of Oncology 2003 14 1 i47 i50
59. Martn A., Fernndez-Jimnez M. C., Caballero M. D., Canales M. A., Prez-Simn J. A., De Garca Bustos J., Vzquez L., Hernndez-Navarro F., San Migue J. F., Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease British Journal of Haematology 2001 113 1 161 171 (Pubitemid 32423317)
60. Bonfante V., Viviani S., Devizzi L., Di Russo A., Di Nicola M., Magni M., Matteucci P., Grisanti S., Valagussa P., Bonadonna G., Gianni A. M., High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease European Journal of Haematology, Supplement 2001 61 64 51 55 (Pubitemid 32589052)
61. Bonfante V., Viviani S., Santoro A., Devizzi L., Di Russo A., Zanini M., Soncini F., Parra H. S., Valagussa P., Bonadonna G., Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease British Journal of Haematology 1998 103 2 533 535 (Pubitemid 28522464)
62. Ferme C., Bastion Y., Lepage E., Berger F., Brice P., Morel P., Gabarre J., Nedellec G., Reman O., Cheron N., Oberlin O., Coiffier B., The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease Annals of Oncology 1995 6 6 543 549
63. Rodriguez J., Rodriguez M. A., Fayad L., McLaughlin P., Swan F., Sarris A., Romaguera J., Andersson B., Cabanillas F., Hagemeister F. B., ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease Blood 1999 93 11 3632 3636 (Pubitemid 29249808)
64. Bartlett N. L., Niedzwiecki D., Johnson J. L., Friedberg J. W., Johnson K. B., van Besien K., Zelenetz A. D., Cheson B. D., Canellos G. P., Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 Annals of Oncology 2007 18 6 1071 1079 (Pubitemid 47053777)
65. Baetz T., Belch A., Couban S., Imrie K., Yau J., Myers R., Ding K., Paul N., Shepherd L., Iglesias J., Meyer R., Crump M., Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group Annals of Oncology 2003 14 12 1762 1767 (Pubitemid 38029048)
66. Pfreundschuh M. G., Rueffer U., Lathan B., Schmitz N., Brosteanu O., Hasenclever D., Haas R., Kirchner H., Koch P., Kuse R., Loeffler M., Diehl V., Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's disease study group Journal of Clinical Oncology 1994 12 3 580 586 (Pubitemid 24079902)
67. Josting A., Nogov L., Franklin J., Glossmann J. P., Eich H. T., Sieber M., Schober T., Boettcher H. D., Schulz U., Mller R. P., Diehl V., Engert A., Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group Journal of Clinical Oncology 2005 23 7 1522 1529
68. Gajewski J. L., Phillips G. L., Sobocinski K. A., Armitage J. O., Gale R. P., Champlin R. E., Herzig R. H., Hurd D. D., Jagannath S., Klein J. P., Lazarus H. M., McCarthy P. L., Pavlovsky S., Petersen F. B., Rowlings P. A., Russell J. A., Silver S. M., Vose J. M., Wiernik P. H., Bortin M. M., Horowitz M. M., Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease Journal of Clinical Oncology 1996 14 2 572 578 (Pubitemid 26051023)
69. Milpied N., Fielding A. K., Pearce R. M., Ernst P., Goldstone A. H., Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease Journal of Clinical Oncology 1996 14 4 1291 1296 (Pubitemid 26105538)
70. Anderson J. E., Litzow M. R., Appelbaum F. R., Schoch G., Fisher L. D., Buckner C. D., Petersen F. B., Crawford S. W., Press O. W., Sanders J. E., Bensinger W. I., Martin P. J., Storb R., Sullivan K. M., Hansen J. A., Thomas E. D., Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience Journal of Clinical Oncology 1993 11 12 2342 2350 (Pubitemid 23353963)
71. Akpek G., Ambinder R. F., Piantadosi S., Abrams R. A., Brodsky R. A., Vogelsang G. B., Zahurak M. L., Fuller D., Miller C. B., Noga S. J., Fuchs E., Flinn I. W., O'Donnell P., Seifter E. J., Mann R. B., Jones R. J., Long-term results of blood and marrow transplantation for Hodgkin's Lymphoma Journal of Clinical Oncology 2001 19 23 4314 4321 (Pubitemid 33096779)
72. Peniket A. J., Ruiz de Elvira M. C., Taghipour G., Cordonnier C., Gluckman E., de Witte T., Santini G., Blaise D., Greinix H., Ferrant A., Cornelissen J., Schmitz N., Goldstone A. H., An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplantation 2003 31 8 667 678 (Pubitemid 36553477)
73. Peggs K. S., Mackinnon S., Exploiting graft-versus-tumour responses using donor leukocyte infusions Best Practice and Research: Clinical Haematology 2001 14 4 723 739 (Pubitemid 34083137)
74. Robinson S. P., Goldstone A. H., Mackinnon S., Carella A., Russell N., De Elvira C. R., Taghipour G., Schmitz N., Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 2002 100 13 4310 4316 (Pubitemid 35429668)
75. Peggs K. S., Hunter A., Chopra R., Parker A., Mahendra P., Milligan D., Craddock C., Pettengell R., Dogan A., Thomson K. J., Morris E. C., Hale G., Waldmann H., Goldstone A. H., Linch D. C., MacKinnon S., Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation Lancet 2005 365 9475 1934 1941 (Pubitemid 40797503)
76. Alvarez I., Sureda A., Caballero M. D., Urbano-Ispizua A., Ribera J. M., Canales M., Garca-Conde J., Sanz G., Arranz R., Bernal M. T., de la Serna J., Dez J. L., Moraleda J. M., Rubi-Flix D., Xicoy B., Martnez C., Mateos M. V., Sierra J., Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol Biology of Blood and Marrow Transplantation 2006 12 2 172 183 (Pubitemid 43138012)
77. Anderlini P., Saliba R., Acholonu S., Giralt S. A., Andersson B., Ueno N. T., Hosing C., Khouri I. F., Couriel D., De Lima M., Qazilbash M. H., Pro B., Romaguera J., Fayad L., Hagemeister F., Younes A., Munsell M. F., Champlin R. E., Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience Haematologica 2008 93 2 257 264 (Pubitemid 351397714)
78. Sureda A., Robinson S., Canals C., Carella A. M., Boogaerts M. A., Caballero D., Hunter A. E., Kanz L., Slavin S., Cornelissen J. J., Gramatzki M., Niederwieser D., Russell N. H., Schmitz N., Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation Journal of Clinical Oncology 2008 26 3 455 462 (Pubitemid 351171699)
79. Anderlini P., Acholonu S. A., Okoroji G. J., Andersson B. S., Couriel D. R., De Lim M. J., Donato M. L., Khouri I. F., Giralt S. A., Ueno N. T., Champlin R. E., Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response Bone Marrow Transplantation 2004 34 6 511 514 (Pubitemid 39264041)
80. Peggs K. S., Sureda A., Qian W., Caballero D., Hunter A., Urbano-Ispizua A., Cavet J., Ribera J. M., Parker A., Canales M., Mahendra P., Garcia-Conde J., Milligan D., Sanz G., Thomson K., Arranz R., Goldstone A. H., Alvarez I., Linch D. C., Sierra J., MacKinnon S., Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes British Journal of Haematology 2007 139 1 70 80 (Pubitemid 47389932)
81. Thomson K. J., Peggs K. S., Smith P., Cavet J., Hunter A., Parker A., Pettengell R., Milligan D., Morris E. C., Goldstone A. H., Linch D. C., Mackinnon S., Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation Bone Marrow Transplantation 2008 41 9 765 770 (Pubitemid 351696339)
82. Moskowitz A. J., Yahalom J., Kewalramani T., Maragulia J. C., Vanak J. M., Zelenetz A. D., Moskowitz C. H., Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma Blood 2010 116 23 4934 4937
83. Forero-Torres A., Leonard J. P., Younes A., Rosenblatt J. D., Brice P., Bartlett N. L., Bosly A., Pinter-Brown L., Kennedy D., Sievers E. L., Gopal A. K., A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma British Journal of Haematology 2009 146 2 171 179
84. Ansell S. M., Horwitz S. M., Engert A., Khan K. D., Lin T., Strair R., Keler T., Graziano R., Blanset D., Yellin M., Fischkoff S., Assad A., Borchmann P., Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma Journal of Clinical Oncology 2007 25 19 2764 2769 (Pubitemid 47123185)
85. Younes A., Forero-Torres A., Bartlett N. L., Multiple complete responses in a phase I dose escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas Blood 2008 112, abstract 1006
86. Bartlett N., Forero-Torrres A., Rosenblatt J., Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30,
87. Dancey G., Violet J., Malaroda A., Green A. J., Sharma S. K., Francis R., Othman S., Parker S., Buscombe J., Griffin N., Chan P. S., Malhotra A., Woodward N., Ramsay A., Ross P., Lister T. A., Amlot P., Begent R., McNamara C., A phase I clinical trial of CHT-25 a I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma Clinical Cancer Research 2009 15 24 7701 7710
88. Younes A., Wedgwood A., McLaughlin P., Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study Blood 2007 110, abstract 2571
89. Dickinson M., Ritchie D., Deangelo D. J., Spencer A., Ottmann O. G., Fischer T., Bhalla K. N., Liu A., Parker K., Scott J. W., Bishton M., Miles Prince H., Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma British Journal of Haematology 2009 147 1 97 101
90. Younes A., Sureda A., ben-Yehuda D., Phase II study of oral panobinostat in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant (ASCT) Haematologica 2009 94, abstract 34
91. Kirschbaum M. H., Goldman B. H., Zain J. M., Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517 Blood 2007 110, abstract 2574
92. Johnston P. B., Inwards D. J., Colgan J. P., Laplant B. R., Kabat B. F., Habermann T. M., Micallef I. N., Porrata L. F., Ansell S. M., Reeder C. B., Roy V., Witzig T. E., A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma American Journal of Hematology 2010 85 5 320 324
93. Zheng B., Georgakis G. V., Li Y., Bharti A., McConkey D., Aggarwal B. B., Younes A., Induction of cell cycle arrest and apoptosis by the proteosome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor- B mutations or activation of the CD30, CD40, and RANK receptors Clinical Cancer Research 2004 10 9 3207 3215 (Pubitemid 38619702)
94. Bll B., Hansen H., Heuck F., Reiners K., Borchmann P., Rothe A., Engert A., Von Strandmann E. P., The fully human anti-CD30 antibody 5F11 activates NF- B and sensitizes lymphoma cells to bortezomib-induced apoptosis Blood 2005 106 5 1839 1842 (Pubitemid 41208602)
95. Younes A., Pro B., Fayad L., Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma Blood 2006 107 4 1731 1732 (Pubitemid 43242417)
96. Blum K. A., Johnson J. L., Niedzwiecki D., Canellos G. P., Cheson B. D., Bartlett N. L., Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206 Leukemia and Lymphoma 2007 48 7 1313 1319 (Pubitemid 47079358)
97. Younes A., Romaguera J., Hagemeister F., McLaughlin P., Rodriguez M. A., Fiumara P., Goy A., Jeha S., Manning J. T., Jones D., Abruzzo L. V., Medeiros L. J., A pilot study of rituximab in patients with recurrent, classic Hodgkin disease Cancer 2003 98 2 310 314 (Pubitemid 36828455)
98. Rehwald U., Schulz H., Reiser M., Sieber M., Staak J. O., Morschhauser F., Driessen C., Rdiger T., Mller-Hermelink K., Diehl V., Engert A., Treatment of relapsed CD20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group Blood 2003 101 2 420 424 (Pubitemid 36077558)
99. Wedgewood A. R., Fanale M. A., Fayad L. E., Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy Blood 2007 110, abstract 215
100. Oki Y., Pro B., Fayad L. E., Romaguera J., Samaniego F., Hagemeister F., Neelapu S., McLaughlin P., Goy A., Younes A., Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma Cancer 2008 112 4 831 836 (Pubitemid 351240577)
101. Bll B., Borchmann P., Topp M. S., Hnel M., Reiners K. S., Engert A., Naumann R., Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma British Journal of Haematology 2010 148 3 480 482
102. Kuruvilla J., Taylor D., Wang L., Blatter C., Keating A., Crump M., Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma Blood 2008 112. abstract no. 3052